The meteoric progress of molecular biology and genetics, the emergence of new methods for studying diseases, and the rise of bioinformatics, have given us hope over the last twenty years that therapeutic innovation would achieve a new level of effectiveness. At the same time, the costs of therapeutic innovation are rising, and the major pharmaceutical groups are abandoning areas that have become unprofitable in relation to the investment required. How can we create new drugs today? Are we going to have more diagnostic tools than new drugs? How can we finance the first clinical trials when the major pharmaceutical groups are waiting for molecules to prove their activity in humans?
The symposium will enable us to sketch out some proposals. Success stories in the fields of drugs and the creation of artificial organs will shed concrete light on the paradigms that need to be established. Finally, the question of financing creativity will also be addressed.
